Giulia Maria Amorelli

Safety and efficacy of risdiplam in patients with type 1 spinal muscular atrophy (FIREFISH part 2): secondary analyses from an open-label trial

Riccardo Masson, Maria Mazurkiewicz-Bełdzińska, Kristy Rose et al. · The Lancet Neurology · 2022 · 96 citations · Full text

Type 1, Firefish Part 2, Rehabilitation +6

Cytomegalovirus anterior uveitis: long-term follow-up of immunocompetent patients

Massimo Accorinti, Marta Gilardi, Maria Pia Pirraglia et al. · Graefe s Archive for Clinical and Experimental Ophthalmology · 2014 · 76 citations

Viral Persistence, Ophthalmology, Virology +4

Short- and mid-term multidisciplinary outcomes of newborns exposed to SARS-CoV-2 in utero or during the perinatal period: preliminary findings

Danilo Buonsenso, Simonetta Costa, Lucia Giordano et al. · European Journal of Pediatrics · 2022 · 44 citations · Full text

Risdiplam treatment has not led to retinal toxicity in patients with spinal muscular atrophy

Robert C. Sergott, Giulia Maria Amorelli, Giovanni Baranello et al. · Annals of Clinical and Translational Neurology · 2020 · 34 citations · Full text

Optic Disk Pit Maculopathy Treatment Using a Human Amniotic Membrane Patch: One-Year Results

Tomaso Caporossi, G. D’Amico, Ruggero Tartaro et al. · American Journal of Ophthalmology · 2022 · 16 citations

Ocular Disease, Ophthalmology, One-year Results +5